DuPont bioscience chief exits on eve of spinoff to head drug development consulting company


Certara announced it has appointed Dr. Feehery as its new Chief Executive Officer effective June 3.

Feehery joins Certara from DuPont, where he has served since 2013 as president of DuPont Industrial Biosciences, a $2.2 billion global biotechnology business.

The DuPont business employs 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets.

Feehery’s exit comes as DuPont and Cortevaare slated to split off into separate companies on Monday and complete a complicated merger-spinoff.

Feehery joined DuPont in 2002 and has prior experience in venture capital and as a consultant for the Boston Consulting Group. Feehery also serves as a board member for West Pharmaceutical Services, a manufacturer of packing components and delivery systems for pharmaceutical, biotech and medical device companies.

Dr. Edmundo Muniz, who has served as Certara CEO since June 2014, will become a member of the Certara Board of Directors and Chair of the Board’s newly-formed Science Committee.

During Muniz’ tenure as CEO, Certara has grown to become the world leader in model-informed decision support solutions for drug development, regulatory science and market/patient access, a release from Certarastated.

“We are very pleased to welcome Bill to Certara. Bill’s broad and diverse background in technology and commercial operations position him well to lead the company. We are confident that his technical, operational and commercial expertise will serve him well as he takes the company to its next level of growth,” said Sheri McCoy, Certara chairman of the board.

“I am excited to join Certara, an exceptional company that is reducing the cost, time, and risk of drug development. I could not have made a better choice than to join the company at this exciting time in its growth trajectory,” said Feehery. “Certara’s track record for optimizing drug development and patient care decision-making by leveraging its integrated portfolio of quantitative and in silico capabilities is impeccable. The company has already had a significant positive impact, helping to bring safer and more effective new therapies to market efficiently. The healthcare field is ripe for accelerated innovation of this type and Certara is poised to lead the market.”

Dr. Feehery holds both a PhD in chemical engineering and an MBA from MIT.

Certara is based in Princeton, NJ.

Facebook Comments